CSL Wins HAE Race For U.S. FDA Approval; Will Orphan Drug Rules Lock The Gate Behind?
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - CSL Behring, a U.S. subsidiary of the Australian-headquartered CSL Limited, announced U.S. FDA approval Oct. 12 of its C1 esterase inhibitor Berinert for treating adults and adolescents with acute abdominal or facial attacks of hereditary angioedema (HAE)
You may also be interested in...
CSL Posts 23 Percent Revenue Growth, Boosted Largely By H1N1 Sales
PERTH, Australia - Melbourne-headquartered CSL attributed its 23 percent revenue growth for the first half of 2010 to it's A/H1N1 vaccine Panvax out of its Biotherapies business unit. Business strategy for the company will focus on geographic expansion in emerging markets and specialty products
CSL Posts 23 Percent Revenue Growth, Boosted Largely By H1N1 Sales
PERTH, Australia - Melbourne-headquartered CSL attributed its 23 percent revenue growth for the first half of 2010 to it's A/H1N1 vaccine Panvax out of its Biotherapies business unit. Business strategy for the company will focus on geographic expansion in emerging markets and specialty products
ViroPharma Looks To Cinryze To Drive Sales As Vancocin Faces Likely Generic Competition
The biotech's HAE drug exceeded sales expectations during the second quarter, but FDA cites the company for misleading promotion.